Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,586 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials.
Tan DJH, Tang ASP, Lim WH, Ng CH, Nah B, Fu C, Xiao J, Koh B, Tay PWL, Tan EX, Teng M, Syn N, Muthiah MD, Tamaki N, Lee SW, Kim BK, Yau T, Vogel A, Loomba R, Huang DQ. Tan DJH, et al. Among authors: tamaki n. Liver Cancer. 2023 Mar 28;12(5):445-456. doi: 10.1159/000529824. eCollection 2023 Oct. Liver Cancer. 2023. PMID: 37901764 Free PMC article.
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Tsuchiya K, et al. Among authors: tamaki n. Cancer. 2014 Jan 15;120(2):229-37. doi: 10.1002/cncr.28384. Epub 2013 Oct 7. Cancer. 2014. PMID: 24122122 Free PMC article. Clinical Trial.
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment.
Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, Komiyama Y, Takaura K, Hayashi T, Kuwabara K, Nakakuki N, Takada H, Ueda M, Tamaki N, Suzuki S, Itakura J, Takahashi Y, Izumi N. Nakanishi H, et al. Among authors: tamaki n. Liver Cancer. 2016 Oct;5(4):257-268. doi: 10.1159/000449337. Epub 2016 Sep 14. Liver Cancer. 2016. PMID: 27781198 Free PMC article.
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, Tamaki N, Takaura K, Komiyama Y, Higuchi M, Kubota Y, Wang W, Okada M, Enomoto N, Izumi N. Takada H, et al. Among authors: tamaki n. PLoS One. 2018 Jun 18;13(6):e0198812. doi: 10.1371/journal.pone.0198812. eCollection 2018. PLoS One. 2018. PMID: 29912922 Free PMC article.
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Tamaki N, Kurosaki M, Yasui Y, Mori N, Tsuji K, Hasebe C, Joko K, Akahane T, Furuta K, Kobashi H, Kimura H, Yagisawa H, Marusawa H, Kondo M, Kojima Y, Yoshida H, Uchida Y, Loomba R, Izumi N. Tamaki N, et al. Clin Infect Dis. 2021 Nov 2;73(9):e3349-e3354. doi: 10.1093/cid/ciaa1307. Clin Infect Dis. 2021. PMID: 33544129 Free PMC article.
1,586 results